Christine V. Sapan, PhD
Founder, Chief Executive Officer
Dr. Christine V. Sapan has been President since September of 2015 and was promoted to CEO and Chairman of the Board early in 2016. Previously, Dr. Sapan held the title of EVP of Research and Development and was responsible for the Company’s development efforts.
Throughout Dr. Sapan’s professional career, she has devoted her efforts to bringing products to market that include successful regulatory applications and launch for devices, biologics and pharmaceuticals. Dr. Sapan has held leadership positions at Neurologix, Nabi Biopharmaceuticals and Beckman Coulter with the objective to complete her mission at a company before seeking new opportunities. Her commitment to Asana’s products and shareholders is unrelenting.
Prior to Asana Medical, Inc., Dr. Sapan was employed with Neurologix, Inc. as the Executive Vice President, Chief Development Officer to advance the molecular genomic medicine programs. In this capacity, she was responsible for developing the gene therapy neuroscience product pipeline through the clinic toward commercialization. Under her leadership, the clinical, regulatory, and manufacturing processes were streamlined and subsequently validated to create a therapeutic for Parkinson’s disease, epilepsy and Huntington’s disease. She was previously employed for 18 years at Nabi Biopharmaceuticals, a vertically integrated company that focused on serious unmet medical needs including infectious diseases using immunotherapy. She served in roles with increasing responsibility as VP, Project Management. During her tenure with Nabi, Dr. Sapan played a key role in the management of the company’s active translational and discovery programs as well as the commercial expansion of its therapeutic products. At Beckman Coulter, a global corporation, Dr. Sapan developed multiple hematology controls that established the market for the early Coulter Counter. During her career, Dr. Sapan has also consulted for a number of technology-based companies, with the primary focus of streamlining their product development to effectively advance to commercialization.
Prior to joining industry, Dr. Sapan spent several years in academia including at Duke University in Immunology as a Howard Hughes Medical Institute Post-Doctoral Fellow and at University of North Carolina performing discovery research in thrombosis and hemostasis. Dr. Sapan has a PhD in Experimental Pathology and an MS in Human Physiology from the University of North Carolina at Chapel Hill. She has published extensively in her areas of scientific interest.
Brian W. Andersen
Chief Business Officer
Mr. Andersen joined Asana Medical as its Chief Business Officer in March 2017 and brings with him an impressive track record in sales and marketing leadership. Over the past 15 years, Brian’s experience includes launching new products, re-introducing and revitalizing stalled sales of existing products, building specialty pharmacy distribution networks, generating and excecuting marketing plans, and establishing a patient reimbursement and support center. As a member of the executive team, Brian will assist with the strategic build-out of the Asana business model and market delivery options, as well as with the development and execution of of the Company’s commercialization and reimbursement plans.
Prior to joining Asana, Brian was the General Manager and Group Vice President of the Orphan Business Unit at Horizon Pharma which he joined in September 2014, through its acquisition of Vidara Therapeutics. While at Horizon, Brian led the integration of Vidara Therapeutics into the newly created Orphan Business Unit at Horizon, as well as the integration of Hyperion Therapeutics, which Horizon bought in March of 2015.
Previous to Horizon Pharma, Brian was co-founder and Vice President of Sales and Marketing at Vidara Therapeutics. At Vidara, he was responsible for the relaunch of ACTIMMUNE® for Chronic Granulomatous Disease (CGD) and severe, malignant osteoporosis (SMO), two ultra-orphan disease states. He was also responsible for all aspects of the commercialization effort, including the establishment of a specialty pharmacy distribution network; the creation of COMPASSTM, a high-touch patient reimbursement and support center; creating the marketing plan; and hiring the sales team. Prior to Vidara, Mr. Andersen led the marketing teams at Lundbeck, Inc. (formerly Ovation) and EKR Therapeutics, where he was responsible for the successful turnaround of PANHEMATIN®, the introduction of the CARDENE® IV Ready-to-Use Bag, and led sales training teams through the launch of SABRIL®. As Regional Business Manager with PDL BioPharma/ESP Pharma, Brian was responsible for managing sales teams in eight states, servicing clients in the hospital and oncology space.
Mr. Andersen holds a BS in biology from the University of Illinois (1997) and an MBA from Northwestern University’s Kellogg School of Management (2006).
Scott Winston, PhD
VP Research & Development
Dr. Winston has focused his professional career spanning over 30 years in product development, manufacturing, preclinical and clinical testing, guiding vaccines, diagnostics, immunotherapeutics and smoking cessation products from inception through regulatory approval.
Dr. Winston holds a BS degree in Zoology from the University of Rhode Island, a PhD in Biology from the University of Colorado and did Post-Doctoral studies in Biochemistry at the University of Colorado, School of Medicine.
Gerard S. Coombs
Founder, Exec VP Operations
Mr. Coombs, co-founder of Asana Medical, Inc., is a business professional with extensive background in C-level management experience at several life sciences companies. Mr. Coombs has utilized his skill set to successfully design and implement operational and strategic programs, secure financing transactions and mergers and acquisitions. Mr. Coombs’ expertise includes operations management, finance and accounting, information technology and human resource management. His industry experience includes pharmaceuticals, medical devices, technology, healthcare, software as a service, traditional software, and consumer products. Mr. Coombs has been involved in the organization of a number of start-up technology companies in the life sciences industry and has conducted the initial public offering and private placement of securities for several companies.
Prior to Asana Medical, Inc., Mr. Coombs, through Global Resource Partners, Inc., served as a Financial Management Consultant for Fuse Science, Inc., a publicly traded consumer products company developing novel delivery systems for sports nutrition and nutraceutical applications, Brickell Biotech, Inc. a development-stage pharmaceutical company focused on the development of innovative, first-in-class dermatological therapeutics, Concordia Pharmaceuticals, Inc. (sold to Kadmon Pharmaceuticals, Inc.) and City Labs, Inc. an early stage company developing long-life Tritium betavoltaic batteries for microelectronics, sensors, and medical devices.
Mr. Coombs also served as Chief Financial Officer for SANO Corporation from 1991-1998, a publicly traded NASDAQ company. Mr. Coombs holds a B.B.A. degree in Accounting and a Certificate in Tax Studies from the University of Miami and has been licensed as a certified public accountant in the State of Florida.
Richard C. Bulman, Jr., Esq.
Founder, VP Legal & Business Affairs
Mr. Bulman is a business and technology lawyer with more than 25 years of experience counseling early-stage and growth ventures including life sciences companies such as IVAX Corporation, SANO Corporation, Concordia Pharmaceuticals, Brickell Biotech and Oncomune. He has conducted and managed activities in more than 50 countries involving business architecture, planning and strategy; intellectual property development, protection, marketing, licensing and sale; debt and equity financing; branding and channel management; and mergers and acquisitions, strategic partnerships and corporate transactions.
He has served in executive and legal positions with such organizations as KL/Gates (formerly Kirkpatrick & Lockhart), Akerman Senterfitt, American Lawyer Media, Diversified Communications Industries and the State of New York.
Mr. Bulman holds a B.A. In Public Affairs from the Rockefeller College of Public Affairs and Policy at The University at Albany, and a J.D. from the Faculty of Law and Jurisprudence at the State University of New York at Buffalo.
Mr. Ramer’s 19-year career as a biomedical engineer in the medical device industry, with a primary focus on research and development adds great value to Asana. He has participated in or led multiple product development programs including stents, a microguidewire, embolic coil, coated vascular graft, synthetic aortic heart valve, orthopedic implants and two laparoscopic surgical devices, among others. He has initiated significant clinical trials for novel medical devices around the world.
Mr. Ramer’s career included a 10-year run at Cordis (a Johnson & Johnson company). He left Cordis to assume his first executive position as Director of R & D for Innovia LLC, an early-stage medical device company, during which Mr. Ramer contributed to or lead the development of multiple new technologies. While at Innovia he commercialized a novel device for Single Port Access Surgery, Innovia’s first commercially launched product.
Mr. Ramer has a BSE and MS in Materials Science and Engineering (Biomaterials specialty) from the University of Florida as well as several years of post-graduate study at the Universities of Utah and Miami. He has eight US patents and others pending, several publications, and a history of speaking engagements at conferences and universities.
Other Key Personnel:
Asana’s team includes seasoned professionals with approximately 80 combined years of experience in the medical device space. All have large company and startup experience and a track record of success, including multiple successful product launches.